SCHEMBL21553669

SCHEMBL21553669

CNC(=O)C(CN)NC(=O)C1CCCN1C(C)=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.46
ITGB1 P05556 1/20 0.42
ITGA4 P13612 1/20 0.42
P2RX7 Q99572 1/20 0.39
OPRM1 P35372 2/20 0.39
CPA1 P15085 1/20 0.39
CPA2 P48052 1/20 0.39
CPA4 Q9UI42 1/20 0.39
REN P00797 1/20 0.38
TACR1 P25103 1/20 0.37
VHL P40337 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
XIAP P98170 1/20 0.36
NTMT1 Q9BV86 1/20 0.36
MMP3 P08254 2/20 0.36
MMP1 P03956 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21553671 0.80 XIAP (0.42) F2OPRM1OPRD1OPRK1XIAP
SCHEMBL19819645 0.80 F2 (0.32) F2ITGB1ITGA4OPRM1
SCHEMBL406540 0.77 P2RX7 (0.45) F2P2RX7CPA1CPA2CPA4
SCHEMBL10136486 0.77 P2RX7 (0.45) F2P2RX7CPA1CPA2CPA4
SCHEMBL12258952 0.77 P2RX7 (0.45) F2P2RX7CPA1CPA2CPA4
SCHEMBL18098145 0.77 F2 (0.50) F2ITGB1ITGA4P2RX7OPRM1
SCHEMBL31181175 0.76 ITGB1 (0.52) F2ITGB1ITGA4P2RX7OPRM1
SCHEMBL19681252 0.76 F2 (0.43) F2ITGB1ITGA4P2RX7REN
SCHEMBL19685306 0.75 F2 (0.52) F2OPRM1VHLNTMT1
SCHEMBL30121019 0.75 ACE (0.49) F2ITGB1ITGA4OPRM1CPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3626732-A1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS Bristol-Myers Squibb Company (US) 2020-03-25 EP disclosed
EP-2970390-B1 MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80(B7-1)/PD-L1 PROTEIN/PROTEIN INTERACTIONS BRISTOL MYERS SQUIBB CO (US) 2019-11-06 EP disclosed